Daiichi Sankyo Offloading 41 Off-Patent Drugs to Alfresa as It Sharpens Focus on Oncology

August 1, 2018
Daiichi Sankyo said on July 31 that it is selling off 41 off-patent brand-name drugs offered by the company and its subsidiary Daiichi Sankyo Espha to Alfresa Pharma, a pharma unit of wholesaler major Alfresa Holdings, beginning in March next...read more